May 11, 2020 / 10:55 AM / 19 days ago

BRIEF-Tasly Pharmaceutical's Unit Signs C-REV License Agreement With Japan's Takara Bio

May 11 (Reuters) - Tasly Pharmaceutical Group Co Ltd :

* SAYS ITS UNIT OBTAINS EXCLUSIVE RIGHT IN CHINA TO PRODUCE AND COMMERCIALIZE PANCREATIC CANCER AND MELANOMA TREATMENT C-REVENUE DEVELOPED BY JAPAN'S TAKARA BIO Source text in Chinese: bit.ly/3drHhrk Further company coverage: (Reporting by Hong Kong newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below